View DividendCell Bio Human TechLtd 경영진경영진 기준 점검 0/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보KwonSun Lee최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율0.2%경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간데이터 없음최근 경영진 업데이트공시 • Mar 04Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea공시 • Feb 27Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 15Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩6,280, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years.공시 • Apr 15Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.분석 기사 • Mar 27Additional Considerations Required While Assessing Cell Bio Human TechLtd's (KOSDAQ:318160) Strong EarningsCell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) announced strong profits, but the stock was stagnant. Our analysis...Buy Or Sell Opportunity • Mar 12Now 23% overvaluedOver the last 90 days, the stock has fallen 18% to ₩7,330. The fair value is estimated to be ₩5,970, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to grow by 33% in the next year.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩6,350, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past year.공시 • Mar 04Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South KoreaValuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩7,610, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 110% over the past year.분석 기사 • Feb 16We Ran A Stock Scan For Earnings Growth And Cell Bio Human TechLtd (KOSDAQ:318160) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,230, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 202% over the past year.분석 기사 • Nov 21Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Business Is Trailing The Industry But Its Shares Aren'tWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...Valuation Update With 7 Day Price Move • Nov 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,450, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past year.분석 기사 • Oct 16Is Now The Time To Put Cell Bio Human TechLtd (KOSDAQ:318160) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...공시 • Sep 19Cell Bio Human Tech Co.,Ltd announced that it expects to receive KRW 3.5 billion in funding from Mirae Asset Securities Co., Ltd.Cell Bio Human Tech Co.,Ltd announced a private placement to issue Zero Coupon Series 1 Unsecured Private Equity Convertible Bonds due September 26, 2032 for gross proceeds of KRW 3,500,000,000 on September 18, 2025. The transaction will include participation from new investor Mirae Asset Securities Co., Ltd. (as the trustee of this fund). The transaction has been approved by shareholders, expected to close on September 26, 2025, 100% convertible into 341,930 shares at a fixed conversion price of KRW 10,236 from October 26, 2025 to August 26, 2032, bears zero coupon rate, zero maturity rate and matures on September 26, 2032.New Risk • Aug 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₩86.5b market cap, or US$62.2m).New Risk • Aug 28New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩74.1b market cap, or US$53.4m).분석 기사 • Aug 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160) Stock Rockets 30% As Investors Are Less Pessimistic Than ExpectedKOSDAQ:A318160 1 Year Share Price vs Fair Value Explore Cell Bio Human TechLtd's Fair Values from the Community and...Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,080, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 148% over the past year.분석 기사 • Jul 21Returns At Cell Bio Human TechLtd (KOSDAQ:318160) Appear To Be Weighed DownIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...분석 기사 • Jun 16Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Shares Climb 26% But Its Business Is Yet to Catch UpDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩62.1b market cap, or US$45.9m).Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,510, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 86% over the past year.분석 기사 • Apr 11Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) 27% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,330, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 32% over the past year.분석 기사 • Mar 21Cell Bio Human TechLtd (KOSDAQ:318160) Could Be Struggling To Allocate CapitalIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...공시 • Feb 27Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea공시 • Feb 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.분석 기사 • Dec 15Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) is...Valuation Update With 7 Day Price Move • Dec 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,055, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past year.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩3,580, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 3.3% over the past year.분석 기사 • Oct 23Is Cell Bio Human TechLtd (KOSDAQ:318160) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩27.2b market cap, or US$19.9m).분석 기사 • Jun 27Cell Bio Human Tech (KOSDAQ:318160) Seems To Use Debt Rather SparinglyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Jun 08New major risk - Revenue and earnings growthEarnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩36.5b market cap, or US$26.4m).공시 • Mar 27Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.분석 기사 • Mar 13Does Cell Bio Human Tech (KOSDAQ:318160) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEOKwonSun Lee (52 yo)no data재임 기간KwonSun Lee serves as CEO & Director of Cell Bio Human Tech Co.,Ltd.View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 03:51종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cell Bio Human Tech Co.,Ltd는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hyun Dong SungKB Securities Co., Ltd.
공시 • Mar 04Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea
공시 • Feb 27Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea
Valuation Update With 7 Day Price Move • May 15Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩6,280, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years.
공시 • Apr 15Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 500 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 500 million worth of shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the share repurchase is compensation for executives and employees. The repurchase program will expire on April 14, 2027. As of April 13, 2026, the company had 9,61,765 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
분석 기사 • Mar 27Additional Considerations Required While Assessing Cell Bio Human TechLtd's (KOSDAQ:318160) Strong EarningsCell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) announced strong profits, but the stock was stagnant. Our analysis...
Buy Or Sell Opportunity • Mar 12Now 23% overvaluedOver the last 90 days, the stock has fallen 18% to ₩7,330. The fair value is estimated to be ₩5,970, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to grow by 33% in the next year.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩6,350, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past year.
공시 • Mar 04Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩7,610, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 110% over the past year.
분석 기사 • Feb 16We Ran A Stock Scan For Earnings Growth And Cell Bio Human TechLtd (KOSDAQ:318160) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,230, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 202% over the past year.
분석 기사 • Nov 21Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Business Is Trailing The Industry But Its Shares Aren'tWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,450, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past year.
분석 기사 • Oct 16Is Now The Time To Put Cell Bio Human TechLtd (KOSDAQ:318160) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
공시 • Sep 19Cell Bio Human Tech Co.,Ltd announced that it expects to receive KRW 3.5 billion in funding from Mirae Asset Securities Co., Ltd.Cell Bio Human Tech Co.,Ltd announced a private placement to issue Zero Coupon Series 1 Unsecured Private Equity Convertible Bonds due September 26, 2032 for gross proceeds of KRW 3,500,000,000 on September 18, 2025. The transaction will include participation from new investor Mirae Asset Securities Co., Ltd. (as the trustee of this fund). The transaction has been approved by shareholders, expected to close on September 26, 2025, 100% convertible into 341,930 shares at a fixed conversion price of KRW 10,236 from October 26, 2025 to August 26, 2032, bears zero coupon rate, zero maturity rate and matures on September 26, 2032.
New Risk • Aug 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₩86.5b market cap, or US$62.2m).
New Risk • Aug 28New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩74.1b market cap, or US$53.4m).
분석 기사 • Aug 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160) Stock Rockets 30% As Investors Are Less Pessimistic Than ExpectedKOSDAQ:A318160 1 Year Share Price vs Fair Value Explore Cell Bio Human TechLtd's Fair Values from the Community and...
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,080, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 148% over the past year.
분석 기사 • Jul 21Returns At Cell Bio Human TechLtd (KOSDAQ:318160) Appear To Be Weighed DownIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
분석 기사 • Jun 16Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Shares Climb 26% But Its Business Is Yet to Catch UpDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (₩62.1b market cap, or US$45.9m).
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,510, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 86% over the past year.
분석 기사 • Apr 11Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) 27% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) shares have been powering on, with a gain...
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,330, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 32% over the past year.
분석 기사 • Mar 21Cell Bio Human TechLtd (KOSDAQ:318160) Could Be Struggling To Allocate CapitalIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...
공시 • Feb 27Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025Cell Bio Human Tech Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 401, simin-daero, dongan-gu, gyeonggi-do, anyang South Korea
공시 • Feb 20Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co.,Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on February 23, 2026. As of February 19, 2025, the company had 776,831 shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
분석 기사 • Dec 15Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Cell Bio Human Tech Co.,Ltd ( KOSDAQ:318160 ) is...
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,055, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past year.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩3,580, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 3.3% over the past year.
분석 기사 • Oct 23Is Cell Bio Human TechLtd (KOSDAQ:318160) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩27.2b market cap, or US$19.9m).
분석 기사 • Jun 27Cell Bio Human Tech (KOSDAQ:318160) Seems To Use Debt Rather SparinglyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Jun 08New major risk - Revenue and earnings growthEarnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 60% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩36.5b market cap, or US$26.4m).
공시 • Mar 27Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces an Equity Buyback for KRW 2,000 million worth of its shares.Cell Bio Human Tech Co., Ltd (KOSDAQ:A318160) announces a share repurchase program. Under the program, the company will repurchase KRW 2,000 million worth of shares pursuant to a contract with Daishin Securities. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on March 26, 2024. As of March 25, 2024, the company had no shares within scope available for dividend and had 3,688 shares in treasury through other repurchase.
분석 기사 • Mar 13Does Cell Bio Human Tech (KOSDAQ:318160) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...